Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of “Reduce” from Brokerages

Sage Therapeutics, Inc. (NASDAQ:SAGE) has earned an average rating of “Reduce” from the twenty research firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, seventeen have issued a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $13.76.

A number of equities research analysts recently commented on the stock. Wedbush lowered their price objective on shares of Sage Therapeutics from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 9th. HC Wainwright reaffirmed a “neutral” rating and issued a $25.00 price target on shares of Sage Therapeutics in a report on Wednesday, October 9th. Raymond James reissued a “market perform” rating on shares of Sage Therapeutics in a research note on Thursday, October 10th. Robert W. Baird reduced their target price on Sage Therapeutics from $13.00 to $9.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 9th. Finally, JPMorgan Chase & Co. dropped their price target on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a research report on Tuesday, August 6th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. increased its position in Sage Therapeutics by 66.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 4,672 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in Sage Therapeutics by 11.3% during the third quarter. Assenagon Asset Management S.A. now owns 186,039 shares of the biopharmaceutical company’s stock worth $1,343,000 after buying an additional 18,814 shares during the period. Creative Planning acquired a new stake in shares of Sage Therapeutics in the third quarter worth $88,000. Inspire Investing LLC raised its stake in shares of Sage Therapeutics by 77.0% in the 3rd quarter. Inspire Investing LLC now owns 57,772 shares of the biopharmaceutical company’s stock valued at $417,000 after acquiring an additional 25,139 shares during the period. Finally, Point72 DIFC Ltd acquired a new position in shares of Sage Therapeutics during the 2nd quarter valued at $153,000. Institutional investors and hedge funds own 99.22% of the company’s stock.

Sage Therapeutics Trading Up 6.6 %

Shares of Sage Therapeutics stock opened at $8.54 on Tuesday. The company has a 50-day moving average of $7.53 and a two-hundred day moving average of $10.10. The stock has a market cap of $513.95 million, a PE ratio of -1.02 and a beta of 0.91. Sage Therapeutics has a 12-month low of $5.84 and a 12-month high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.02). The firm had revenue of $8.65 million for the quarter, compared to analyst estimates of $8.85 million. Sage Therapeutics had a negative return on equity of 55.87% and a negative net margin of 458.30%. The business’s revenue for the quarter was up 249.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.68) earnings per share. On average, sell-side analysts forecast that Sage Therapeutics will post -6.43 EPS for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.